Perspective
SARS-CoV-2 virological and genomic studies in a favipiravir clinical trial cohort
Author(s): Caroline Thomas*
Favipiravir has been shown to reduce viral load and decrease the duration of symptoms in several clinical investigations. The viability of SARS-CoV-2 in the setting of favipiravir treatment, as well as the risk of resistance, are unknown. Between March and May 2020, we sequenced SARS-CoV-2 in nasopharyngeal tissues taken from patients who took part in a randomized clinical trial of favipiravir at hospitals across Japan. Those who remained RT-PCR-positive 5-8 days after starting favipiravir medication had their genomes sequenced in pairs. The cytopathic impact was investigated in daily nasopharyngeal tissues from 69 individuals who were RT-PCR positive at the time of randomization (CPE). Early in the experiment, some strains belonged to clade 19 B, while the majority belonged to clade 20 B. The median period from the beginning of the condition to the discovery of a negative CPE wa.. Read More»
DOI:
10.37532/puljcmid.2022.5(3).22-23
+447723598358
